Researchers use advanced technology to identify proteomes of Th17 and iTreg cells

T helper 17 (Th17) cells belong to a group of T cells with essential functions in autoimmune diseases and inflammation. Regulatory T cells (iTregs) are T cells with a suppressive function to maintain self-tolerance and prevent autoimmune responses. Researchers from Turku Centre for Biotechnology and Aalto University together utilized the advanced technology called label-free quantitative proteomics to identify the proteomes of Th17 and iTreg cells.

Proteins are one of the major biomolecules that form the functional and structural entity of a living cell. Mass spectrometry-based quantitative proteomics can be used to determine the set of proteins expressed by a cell, tissue, or organism at a certain time.

The immune system defends the body against harmful pathogens and tumours, and also provides self-tolerance. T helper cells are major components of the adaptive system, and they play critical roles in controlling immune reactions.

During her postdoctoral study at the National Institutes of Health (NIH), USA, Dr. Zhi Chen started working on Th17 cells, a subset of helper T cells with an important role in autoimmune inflammation.

The label-free quantitative proteomics technology has been established at the Turku Centre for Biotechnology. Using this technology, Chen's research team in collaboration with computational scientists from Aalto University and scientists from the University of Turku, Åbo Akademi University and the University of Maryland generated a resource that was used to identify over 4000 proteins expressed in Th17 and iTreg cells.

- We also combined analysis of proteome and gene expression data and discovered protein expression changes that were not associated with changes at the transcriptional level, says Chen.

- These identified proteins can potentially be targeted in immunotherapy, especially in disease conditions like cancer and autoimmunity, believes Chen.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
Cancer Research UK invests £14 million to transform London into cancer biotherapeutics hub